# Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

Study · id `cardio:ct-nct02919059` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02919059](<https://clinicaltrials.gov/study/NCT02919059>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02919059

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 159 participants.

## Technical summary

Registry record NCT02919059. Randomized; double masking; primary purpose treatment. Start 2016-12-13 (actual); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 159 participants (planned count; ClinicalTrials.gov record NCT02919059, source copy `cardio:ctgov-nct02919059-2017-03-29`, retrieved 2026-10-26)
- Started: 2016-12-13 (actual) (ClinicalTrials.gov record NCT02919059, source copy `cardio:ctgov-nct02919059-2017-03-29`, retrieved 2026-10-26)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT02919059, source copy `cardio:ctgov-nct02919059-2017-03-29`, retrieved 2026-10-26)
- Completion: 2019-08 (anticipated) (ClinicalTrials.gov record NCT02919059, source copy `cardio:ctgov-nct02919059-2017-03-29`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT02919059, source copy `cardio:ctgov-nct02919059-2017-03-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02919059-2017-03-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dapagliflozin 10 mg
- Intervention (Drug): Glimepiride 4 mg
- Lead sponsor: IInstituto Gallego de Medicina Vascular
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: d954ac699a58c3afab96b736a6b6047e8a3de975b9226126eb9cccf4750d5cef
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
